Arvinas anticipates U.S. ARV-102 PSP trial by end of 2026 while maintaining cash runway into second half of 2028
Arvinas, Inc · PHARMACEUTICAL PREPARATIONS · Now $8.58
-5.1% in 3d after detection
Post-detection moves
1h
—
1d
+3.1%
3d
-5.1%
7d
-4.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS